TP53 and B-cell chronic lymphocytic leukemia: The ELEVATE-RR trial50 compared acalabrutinib with ibrutinib in relapsed or refractory CLL patients with at least one high-risk genetic alteration (mutation and/or del(17p/TP53) or del(11q)).